Retatrutide: Triple Agonist Research Guide [2026]

Retatrutide: What the Research Shows

Retatrutide (LY3437943) represents the most advanced multi-receptor agonist in metabolic research — a triple-acting peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, retatrutide has produced the highest weight loss figures ever recorded for any anti-obesity compound in clinical trials, with phase 2 data showing up to 24.2% body weight reduction at 48 weeks.

The addition of glucagon receptor agonism to the established GLP-1/GIP dual agonist framework distinguishes retatrutide from predecessors like semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP). Glucagon receptor activation adds thermogenic energy expenditure and enhanced lipid oxidation effects that may explain the incremental efficacy. Proxiva Labs provides research-grade retatrutide for qualified investigators, and our research hub covers developments across the incretin agonist class.

The Incretin System: GLP-1, GIP, and Glucagon

GLP-1 (Glucagon-Like Peptide-1)

GLP-1 reduces appetite through central hypothalamic signaling, stimulates glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying. It is the established mechanism behind semaglutide and liraglutide.

GIP (Glucose-Dependent Insulinotropic Polypeptide)

GIP is the other major incretin hormone, responsible for approximately 50% of the meal-stimulated insulin response. Beyond insulin secretion, GIP receptors in adipose tissue regulate lipid storage and mobilization, while central GIP receptors influence appetite and energy balance. Tirzepatide was the first drug to leverage dual GLP-1/GIP agonism.

Glucagon

Glucagon is traditionally viewed as a counter-regulatory hormone that raises blood glucose through hepatic glycogenolysis and gluconeogenesis. However, glucagon also stimulates energy expenditure through hepatic thermogenesis, promotes fatty acid oxidation, and reduces appetite through central mechanisms. These catabolic effects make glucagon receptor agonism a compelling addition to the incretin framework for weight management.

Retatrutide Mechanism of Action

Retatrutide is a single peptide that engages three distinct G-protein coupled receptors simultaneously, with carefully tuned potency at each:

• GLP-1 receptor agonism — Appetite suppression, insulin secretion, cardiovascular protection
• GIP receptor agonism — Enhanced insulin response, adipose tissue metabolism, central appetite effects
• Glucagon receptor agonism — Increased energy expenditure, hepatic lipid oxidation, thermogenesis

The relative potency at each receptor is engineered to maximize metabolic benefit while managing the glycemic effects of glucagon. The GLP-1 and GIP components provide sufficient insulin-stimulating activity to counterbalance glucagon’s hyperglycemic potential, allowing the metabolic benefits of all three pathways to be captured (Jastreboff et al., 2023).

Phase 2 Clinical Trial Results

The pivotal phase 2 trial randomized 338 adults with BMI 30-50 (or 27-50 with weight-related comorbidities) to retatrutide (1, 4, 8, or 12mg weekly with different titration schedules) or placebo for 48 weeks.

Weight Loss Results

• 12mg dose (rapid titration): -24.2% body weight at 48 weeks
• 12mg dose (standard titration): -22.8% body weight
• 8mg dose: -22.1% body weight
• 4mg dose: -17.1% body weight
• Placebo: -2.1% body weight

At the 12mg dose, 100% of participants achieved ?5% weight loss, 93% achieved ?10%, 83% achieved ?15%, and 63% achieved ?20%. These response rates exceed all previously published data for any anti-obesity medication (Jastreboff et al., 2023).

Weight Loss Trajectory

Notably, the weight loss curves at the 8mg and 12mg doses had not plateaued at 48 weeks, suggesting that maximum weight reduction may not have been reached. This ongoing trajectory distinguishes retatrutide from other agents that typically reach plateau at 40-60 weeks.

Metabolic Effects

Glycemic Control

In the subset of participants with type 2 diabetes (separate phase 2 trial), retatrutide reduced HbA1c by up to 2.16% from baseline. Fasting glucose and postprandial glucose excursions were significantly improved across all active dose groups.

Lipid Profile

Retatrutide improved multiple lipid parameters including triglycerides (reduced 30-45%), LDL cholesterol, VLDL, and apolipoprotein B. The lipid improvements exceeded those seen with semaglutide, potentially attributable to glucagon-mediated hepatic lipid oxidation.

Insulin Sensitivity

HOMA-IR (a marker of insulin resistance) improved significantly with retatrutide treatment, reflecting both direct incretin effects on insulin signaling and indirect benefits from fat mass reduction.

Liver Fat Reduction (MASLD/NAFLD)

One of retatrutide’s most striking findings involved hepatic fat content. MRI-based proton density fat fraction (PDFF) measurements showed:

• Up to 82-86% relative reduction in liver fat at the 12mg dose
• Complete normalization of liver fat (<5% PDFF) in the majority of treated participants
• Results far exceeding those seen with GLP-1 agonists alone

The pronounced hepatic fat reduction is attributed to glucagon receptor-mediated enhancement of hepatic fatty acid oxidation — a mechanism absent in pure GLP-1 or dual GLP-1/GIP agonists. This has generated significant interest in retatrutide for MASLD/MASH research, with a dedicated phase 2 trial underway.

Cardiovascular Implications

While retatrutide does not yet have dedicated cardiovascular outcomes trial data (unlike semaglutide’s SELECT trial), the metabolic profile — substantial weight loss, lipid improvement, liver fat reduction, and inflammatory marker reduction — suggests potential cardiovascular benefit. GLP-1 receptor agonism has established cardioprotective effects, and glucagon-mediated improvements in hepatic lipid metabolism may provide additional vascular benefits.

Retatrutide vs Semaglutide

Retatrutide vs Tirzepatide

Tirzepatide (dual GLP-1/GIP) produced ~22.5% weight loss in SURMOUNT. Retatrutide’s ~24% in phase 2 represents an incremental improvement, attributed to the added glucagon component. The glucagon receptor activation provides additional thermogenic energy expenditure and hepatic fat oxidation that GIP agonism alone does not deliver. However, direct head-to-head trials are needed for definitive comparison.

The Role of Glucagon Receptor Activation

The glucagon component is what makes retatrutide unique. Glucagon receptor activation produces:

• Hepatic thermogenesis — Glucagon stimulates mitochondrial uncoupling and heat production in the liver
• Enhanced lipid oxidation — Glucagon promotes hepatic fatty acid beta-oxidation, explaining the dramatic liver fat reductions
• Amino acid catabolism — Increased gluconeogenesis from amino acids, potentially contributing to the energy deficit
• Appetite reduction — Central glucagon receptor activation provides additional satiety signals
• Cardiovascular effects — Glucagon has positive inotropic and chronotropic effects on the heart

Research Protocols and Dosing

• Phase 2 dosing: Titrated over 4-8 weeks to target doses of 4mg, 8mg, or 12mg SC weekly
• Titration schedule: Start at 0.5mg weekly, increase by 0.5-2mg every 2-4 weeks based on tolerability
• Phase 3 doses: Expected to focus on 8mg and 12mg based on phase 2 efficacy
• Preclinical dosing: 10-100 nmol/kg SC in rodent metabolic studies
• Storage: 2-8°C; protect from light; lyophilized form stable at -20°C

Safety Profile and Adverse Events

Phase 2 safety data showed:

• GI effects: Nausea (25-49%), diarrhea (18-35%), vomiting (9-22%) — dose-dependent, mitigated by slow titration
• Decreased appetite: Reported as adverse event in 10-14% — consistent with mechanism
• Heart rate: Small increases (2-4 bpm) observed, consistent with GLP-1 agonist class
• Liver enzymes: Transient ALT elevations in some participants, generally resolving
• Hypoglycemia: Low incidence without concomitant insulin or sulfonylurea use
• No pancreatitis signal in phase 2 data (monitoring continues in phase 3)

Frequently Asked Questions

What makes retatrutide different from semaglutide and tirzepatide?

Retatrutide is the only approved or late-stage compound that activates three receptors: GLP-1, GIP, and glucagon. Semaglutide activates only GLP-1; tirzepatide activates GLP-1 and GIP. The glucagon component adds thermogenic energy expenditure and enhanced liver fat reduction.

Is 24% weight loss realistic in clinical practice?

Phase 2 trials typically show slightly larger effects than phase 3 due to smaller sample sizes and more selected populations. However, even with some attenuation, retatrutide is expected to produce the largest weight reductions of any available agent.

When will retatrutide be available?

Retatrutide is currently in phase 3 clinical trials. Regulatory submission and approval timelines depend on trial completion and regulatory review, likely in 2026-2027. Research-grade retatrutide is available for qualified investigators.

Conclusion

Retatrutide represents the next evolution in multi-receptor metabolic therapeutics. By adding glucagon receptor agonism to the established incretin framework, it achieves unprecedented weight loss, dramatic liver fat reduction, and comprehensive metabolic improvement. As phase 3 trials progress, retatrutide may redefine expectations for peptide-based metabolic interventions.

Explore retatrutide, semaglutide, tirzepatide, and other metabolic compounds in our research catalog.